louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06017102: Wired Magnetically Assisted Capsule Endoscopy and Esophageal Varices
Official title: Difference in Aerosol-generating Amount Between Wired Magnetic-assisted Capsule Endoscopy System and Esophagogastroduodenoscopy Examination of Varices in Biliary Atresia Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Esophageal Varices
Keywords: upper endoscopy
biliary atresia
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: Insight Medical Solutions
First posted: 2023-08-30
Enrollment: 50
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The goal of this clinical trial is to compare the safeness and effectiveness of traditional esophagogastroduodenoscope (EGD) and wired magnetically assisted capsule endoscopy (MACE) in the diagnosis of esophageal varices in biliary atresia (BA) patients. The main questions it aims to answer are:

* Subjects who do wired magnetically assisted capsule endoscopy do not need to open the mouths during the process, this study also want to know whether wired magnetically assisted capsule endoscopy can reduce the generation of droplets.
* Diagnostic accuracy between traditional esophagogastroduodenoscope and wired magnetically assisted capsule endoscopy in biliary atresia patients with esophageal varices.

Participants will do either traditional esophagogastroduodenoscope or wired magnetically assisted capsule endoscopy.


Eligibility criteria: Inclusion Criteria:

* Biliary atresia patients \> 6 years old
* Vital signs are stable
* Without acute gastrointestinal bleeding

Exclusion Criteria:

* Patients with metal implants, metal stent, artificial joints, bone plates, and bone screw
* Patients with electronic devices, such as pacemakers, cochlear implants, or other implanted electronic medical devices
* Throat or esophageal obstruction leading to dysphagia patients
* Consciousness disturbance patients unable to swallow
* Patients with acute upper gastrointestinal bleeding
* Patients with platelet lower than 40K or PT INR \> 1.5

Primary outcomes:
measure: Aerosol-generating amount
timeFrame: 1-2 days
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei City
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
References:
Clinical trial NCT00259402: Oxaliplatin in Esophagus Cancer (Advanced) 1st Line
Official title: Phase II Open-label Single Arm Study of Oxaliplatin Combined With Cisplatin and 5FU in Advanced Esophagus Cancer Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Esophageal Neoplasms
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2005-11-29
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: * To determine the activity and efficacy of the schema specified as dose regimen
* To determine the safety and tolerability of the oxaliplatin-cisplatin and 5FU


Eligibility criteria: Inclusion Criteria:

* ECOG 0-1
* Patients with histologically proven epidermoid carcinoma or adenocarcinoma of esophagus or stomach, with unresectable or metastatic disease;
* No previous treatment with chemotherapy or radiotherapy
* Measurable lesion (uni or bidimensional)

Exclusion Criteria:

* Creatinin clearance \<50 mL/min
* Total bilirubin \>1.5\*ULN (Upper Limit of Normal)
* AST/ALT \> 2.5\*ULN
* Total White Blood Cell \<1.500.000/mL
* Platelet count \<100.000.000/mL
* symptomatic sensitive peripheral neuropathy
* pregnant or breast-feeding women

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Efficacy endpoints include tumor response, progression free and overall survival.
timeFrame: Throughout the whole study
Secondary outcomes:
measure: Safety endpoints include summary of adverse events assessed by history, physical exams and laboratory evaluations.
timeFrame: Throughout the whole study duration
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: José Mª Taboada
role: STUDY_DIRECTOR
References:
Clinical trial NCT06873802: ZTE MRI Pulse Sequence Use for Visualization of Bone Cement, Breast Biopsy Markers
Official title: ZTE MRI Pulse Sequence Use for Visualization of Bone Cement, Breast Biopsy Markers
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Breast Carcinoma
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Institute for Biomedical Imaging and Bioengineering (NIBIB)
First posted: 2025-03-13
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy individuals that can receive a non-contrast enhanced breast MRI

Brief summary: This study is being done to determine if a clinically available MRI sequence called ZTE imaging better visualizes breast biopsy markers made of bone cement compared to the currently used breast biopsy markers made of metal.

Detailed description: PRIMARY OBJECTIVE:

I. To demonstrate that clinically available ZTE imaging allows for better visualization of bone cement breast biopsy markers when compared to conventional breast biopsy markers and pulse sequences.

OUTLINE: This is an observational study.

Participants undergo standard of care MRI breast imaging with conventional or bone cement breast biopsy markers and complete a questionnaire on study.

Eligibility criteria: Inclusion Criteria:

* Age of 18 or older

Exclusion Criteria:

* Cardiac pacemaker
* Implanted cardiac defibrillator
* Internal pacing wires
* Cerebral, carotid, or aortic aneurysmal clips
* Cochlear implants
* Implanted tissue expanders
* Claustrophobia
* Cannot lay prone

  * Pregnant

Primary outcomes:
measure: Bone cement marker (BCM) images compared to conventional images
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic in Rochester
name: Christine U. Lee, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03106402: Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification
Official title: Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification
Lead sponsor: Kyungpook National University Hospital
Sponsor class: OTHER
First posted: 2017-04-10
Enrollment: 316
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This retrospective chart review was of consecutive patients who had phacoemulsification and were treated postoperatively at the Kyungpook National University Hospital, Daegu, Korea, from Oct 2013 to June 2015.

Brief summary: To assess the incidence, risk factors and clinical courses of cystic macular lesions (CMLs) after uncomplicated phacoemulsification and evaluate the efficacy of topical NSAIDs on the prevention of pseudophakic cystic macular lesions

Detailed description: 344 Patients undergoing uncomplicated standard phacoemulsification at Kyungpook National University Hospital from 2013 to 2015 were reviewed. CMLs, which is any cystic fluid collections after cataract surgery, were confirmed by preoperative and postoperative optical coherence tomography(OCT) on preoperative, postoperative 1month and 3months examinations. CMLs were classified into two groups: cystic macular edema(CME) and microcystic macular edema(MME).

Eligibility criteria: Inclusion Criteria:

* patients who had phacoemulsification and were treated postoperatively at the Kyungpook National University Hospital, Daegu, Korea, from Oct 2013 to June 2015.

Exclusion Criteria:

* patients had complicated cataract surgery (eg, significant corneal edema, posterior capsule rupture, vitreous loss, dropped nuclear material, retained cortical material, or an IOL not placed in the capsular bag)

Primary outcomes:
measure: Incidence of CMLs
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Kyungpook National University Hospital
name: Hong Kyun Kim, M.D. PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00364702: Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder
Official title: Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: ADHD
Keywords: Virtual Reality
ADHD
Methylphenidate
Lead sponsor: Shaare Zedek Medical Center
Sponsor class: OTHER
First posted: 2006-08-16
Enrollment: 40
Sex: ALL
Minimum age (years): 10
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: DIAGNOSTIC

Brief summary: Using a virtual reality program in screening and treatment of ADHD.

Detailed description: Virtual Reality is a novel program designed to imitate a real classroom environment including various distractions. It includes a head monitor to track eye movements Children aged 10-20 years with ADHD will use the program with and without methylphenidate(1 mg/kg). Their results will be compared to a control group.

Parental consent will be obtained.

Eligibility criteria: Inclusion Criteria:

Clinical diagnosis of ADHD-DSM4 criteria AGE 10-20 YEARS normal neurological examination IQ\>80

Exclusion Criteria:

ABNORMAL NEUROLOGICAL STATUS

Primary outcomes:
measure: Virtual Reality program test results
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Shaari Zedek Pediatric Neurology Unit
Study officials:
affiliation: Shaari Zedek Pediatric Neurology Unit
name: V. Gross, Prof/ md
role: STUDY_CHAIR
References:
Clinical trial NCT04880902: Volumetric Pouch Study After Laparoscopic Sleeve Gastrectomy
Official title: Volumetric Pouch Study After Laparoscopic Sleeve Gastrectomy: Effect of the Pouch Size on Excessive Weight Loss and Weight Regain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bariatric Surgery Candidate
Obesity, Morbid
Keywords: Laparoscopic Sleeve Gastrectomy
gastric reservoir
Multi-slice computer tomography
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2021-05-11
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aimed to evaluate Laparoscopic Sleeve Gastrectomy in the treatment of morbidly obese patients pre and post-operatively after 3 months, 6 months, and 1-year follow-up and assess the volumetric changes of the gastric reservoir 1 year after LSG using multi-slice computer tomography.


Eligibility criteria: Inclusion Criteria:

* BMI of \> 40 kg/m 2 or \> 35 kg/m2 with comorbidities e.g. hypertension and type 2 DM.
* All patients failed in supervised conservative management for obesity for at least 2 years.

Exclusion Criteria:

* BMI \> 60
* previous bariatric surgery
* symptomatic reflux oesophagitis disease, gastric pathology (tumor, active peptic ulcer)
* Significant psychological disorder, active alcohol or substance abuse
* severe eating disorders (bulimia)
* severe systemic disease making anesthesia or surgery prohibitively risky (American Society of Anesthesiologists (ASA) class IV

Primary outcomes:
measure: Gastric volume after surgery
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Kafr Ash Shaykh
country: Egypt
facility: Kafrelsheikh university
Study officials:
References:
Clinical trial NCT01918202: A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers
Official title: A Phase 1, Open-label Adaptive Design Study To Evaluate Pde10 Enzyme Occupancy As Measured By Positron Emission Tomography (Pet) Following Single Oral Dose Administration Of Pf-02545920 In Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Enzyme occupancy
PET
Phosphodiesterase 10 inhibitor
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2013-08-07
Enrollment: 9
Sex: MALE
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This Phase 1 study will evaluate PDE10 enzyme occupancy using Positron Emission Tomography after a single dose of PF-02545920 in Healthy male volunteers.


Eligibility criteria: Inclusion Criteria:

* healthy male volunteers

Exclusion Criteria:

* History of orthostatic hypotension
* History of prior radiation exposure for research purposes, or radiation therapy

Primary outcomes:
measure: Central PDE10A enzyme occupancy values in the striatum.
timeFrame: Day 10
Secondary outcomes:
measure: Central PDE10A enzyme occupancy values in the globus pallidus, in the caudate and in the putamen (separately).
timeFrame: Day 10
measure: Maximum Observed Plasma Concentration (Cmax)
timeFrame: Day 10
measure: Time to Reach Maximum Observed Plasma Concentration (Tmax)
timeFrame: Day 10
measure: Average serum concentration
timeFrame: Day 10
Other outcomes:
Locations:
city: Huddinge
country: Sweden
facility: Karolinska Trial Alliance (KTA) M62
state: Stockholm
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
citation: Delnomdedieu M, Forsberg A, Ogden A, Fazio P, Yu CR, Stenkrona P, Duvvuri S, David W, Al-Tawil N, Vitolo OV, Amini N, Nag S, Halldin C, Varrone A. In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects. Neuropharmacology. 2017 May 1;117:171-181. doi: 10.1016/j.neuropharm.2017.01.016. Epub 2017 Jan 22.
Clinical trial NCT00658502: Ocular Response Analyzer Assessment of Intraocular Pressure and Corneal Biomechanical Properties in Myopic and Anisometropic Patients Under Atropine Treatment
Official title: Ocular Response Analyzer Assessment of Intraocular Pressure and Corneal Biomechanical Properties in Myopic and Anisometropic Patients Under Atropine Treatment
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Myopia
Anisometropia
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2008-04-15
Enrollment: 100
Sex: ALL
Minimum age (years): 6
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: age under 25 year old with or without myopia

Brief summary: Our study has three parts has three parts, and the main aim of the study is to find out if corneal hysteresis was associated with myopia or even a predictor of myopia poor control predictor:

* Part 1 of our study: patients with anisomeropia whose spherical equivalent refraction as measured by cycloplegic autorefraction between the two eyes differ greater than 1.5 D.
* Part 2 of our study: Minus spherical equivalent refraction as measured by cycloplegic autorefraction.
* Part 3 of our study: patients with minus spherical equivalent refraction as measured by cycloplegic autorefraction who are under regular atropine for the treatment of myopia;patients who are prescribed with atropine treatment are in need of myopia control instead of for research interest


Eligibility criteria: Inclusion Criteria:

1. Normal ocular health other than myopia or anisometropia
2. In good general health with no history of prematurity or cardiac or significant respiratory diseases
3. No allergy to atropine, tropicamide, proparacaine, and benzalkonium chloride
4. No previous or current use of contact lenses, bifocals, progressive addition lenses
5. No amblyopia or manifest strabismus, including intermittent tropia

Exclusion Criteria:

1. presence of keratoconus or other corneal disease
2. previous eye drops usage except Atropine
3. major ocular surgery history (including refractive surgery, scleral buckle, glaucoma filtering, cornea transplant, cataract and vitreoretinal surgery)
4. presence of other ocular conditions such as glaucoma, uveitis, or other ocular inflammatory or vitreoretinal diseases.

Primary outcomes:
measure: axial length, corneal hysteresis
timeFrame: 3 month
Secondary outcomes:
measure: Refractive error, visual acuity, , intraocular pressure, , and corneal thickness
timeFrame: 3 month
Other outcomes:
Locations:
city: Pan-chiao
country: Taiwan
facility: Far Eastern Memorial Hospital
state: Taipei county
Study officials:
References:
Clinical trial NCT06556602: Methadone Patient Access to Collaborative Treatment
Official title: Methadone Patient Access to Collaborative Treatment (MPACT)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Opioid Use Disorder
Staff
Patients
Keywords: Methadone
Lead sponsor: University of Arizona
Sponsor class: OTHER
First posted: 2024-08-16
Enrollment: 1080
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Hybrid Type 1, 18-month simultaneous cluster randomized controlled trial in 30 clinics
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The trial of Methadone Patient Access to Collaborative Treatment (MPACT) will establish the impact of the intervention on patient outcomes of methadone treatment retention and in treatment overdose.

It will also establish the impact of patient and staff trauma symptoms and clinic practice change on MPACT intervention implementation.

Detailed description: This MPACT trial will involve finalizing the refined MPACT intervention (materials, training) and conducting a Hybrid Type 1, 15-month cluster randomized controlled trial in 30 clinics with 600 patients (20/clinic) and 480 staff (18/clinic) to assess MPACT effect on patient outcomes and examine the relationship between staff trauma outcomes and MPACT implementation. R33 Specific AIMS:

AIM 1: Quantify the effects of MPACT on methadone treatment (MMT) practice change and opioid treatment program (OTP) culture.

AIM 2: Determine the efficacy of MPACT on MMT retention, in-MMT overdose and patient and staff post traumatic stress symptoms (PTSS) outcomes.

AIM 3: Evaluate the effect of patient and staff trauma symptoms on primary outcomes and staff MPACT implementation.

Eligibility criteria: Inclusion Criteria:

* Staff providing methadone treatment services at the enrolled opioid treatment programs

Exclusion Criteria:

* Patients receiving methadone treatment at the enrolled opioid treatment programs

Primary outcomes:
measure: Days in Treatment to treatment interruption
timeFrame: 18 months
measure: Time to treatment cessation
timeFrame: 18 months
measure: In Treatment- Point in time
timeFrame: 18 months
measure: Number of patients reporting opioid overdoses while in methadone treatment
timeFrame: 18 months
Secondary outcomes:
measure: Number of staff experiencing vicarious (work related) stress
timeFrame: 18 months
measure: Number of patients and staff experiencing post traumatic stress symptoms
timeFrame: 18 months
Other outcomes:
Locations:
city: Tucson
country: United States
facility: University of Arizona College of Medicine
state: Arizona
Study officials:
References:
Clinical trial NCT03616002: Effects of Hookah (Waterpipe) Smoking on Blood Vessel Function
Official title: Effects of Hookah Smoking on Vascular Regulation: Novel Insight Into Endothelial Function
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Hookah Smoking
Lead sponsor: Cedars-Sinai Medical Center
Sponsor class: OTHER
Collaborators: name: University of California, Los Angeles
name: University of California, San Francisco
First posted: 2018-08-06
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 29
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this study is to assess the acute effects of Hookah (waterpipe) smoking on blood vessel function. Hookah smoking has been shown to immediately increase blood pressure and heart rate which could result in damage in the inner lining of the body's blood vessels.

Detailed description: The investigators will measure acute endothelial and vascular changes before and after a 30-minute Hookah smoking session in a controlled laboratory environment to: (1) Determine the acute effects of Hookah smoking on large-vessel endothelial vasodilator function measured by brachial artery flow mediated dilation; (2) Determine the acute effects of Hookah smoking on micro-vessel endothelial function as measured by reactive hyperemia peripheral arterial tonometry; (3) Determine the acute effects of Hookah smoking on pulse wave velocity and aortic pressure waveform measured by pulse tonometry.

Eligibility criteria: Inclusion Criteria:

* 18 to 29 years of age
* Habitual Hookah smoker defined as having smoked Hookah \>=12 times in the past 12 months
* Have not smoked cigarettes within the past 12 months

Exclusion Criteria:

* History of cardiopulmonary, diabetes, dyslipidemia or psychiatric disease
* Exhaled carbon monoxide level \>10 ppm
* BP \< 140/90 mmHg
* BMI \<18.5 or \> 30 kg•m2
* Resting heart rate \> 100 beats/min
* Taking prescription medication
* History of illicit drug use
* Pregnant

Primary outcomes:
measure: Brachial artery flow-mediated dilation
timeFrame: change from baseline to immediately after smoking
Secondary outcomes:
measure: Reactive hyperemia peripheral arterial tonometry
timeFrame: change from baseline to immediately after smoking
Other outcomes:
measure: Pulse wave velocity
timeFrame: change from baseline to immediately after smoking
measure: aortic pressure waveform
timeFrame: change from baseline to immediately after smoking
Locations:
city: Los Angeles
country: United States
facility: Cedars-Sinai Medical Center
state: California
Study officials:
affiliation: Cedars-Sinai Medical Center
name: Florian Rader, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rezk-Hanna M, Mosenifar Z, Benowitz NL, Rader F, Rashid M, Davoren K, Moy NB, Doering L, Robbins W, Sarna L, Li N, Chang LC, Elashoff RM, Victor RG. High Carbon Monoxide Levels from Charcoal Combustion Mask Acute Endothelial Dysfunction Induced by Hookah (Waterpipe) Smoking in Young Adults. Circulation. 2019 May 7;139(19):2215-2224. doi: 10.1161/CIRCULATIONAHA.118.037375.